Long‐term outcomes, quality of life, and costs of treatment modalities for T1–T2 lip carcinomas
Oral Diseases · 2024
DOI: 10.1111/odi.14723 ↗At a glance
Journal article in Oral Diseases, 2024. Written by Kira S van Hof and 9 co-authors. Institution: Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Major MEDLINE topics: Quality of Life, Lip Neoplasms, Brachytherapy, Mohs Surgery. Cited 7 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
Early stage lip squamous cell carcinoma (lip SCC) can be treated with conventional excision, Mohs micrographic surgery (MMS), or brachytherapy. The aim of this retrospective study was to describe the medical outcomes, patient‐reported outcomes, and costs of these treatments.
Methods
A retrospective cohort study of T1–T2 lip SSCs treated between 1996 and 2019. Medical outcomes, recurrences, and survival were retrieved from medical records. Facial appearance, facial function, and Quality of Life (QoL) were measured with the Face‐Q H&N and EQ‐5D‐5L questionnaires. Costs were also calculated.
Results
Of the 336 lip SCCs, 122 were treated with excision, 139 with MMS, and 75 with brachytherapy. Locally, the recurrence rate was 2.7% and regionally 4.8%. There were 2% disease‐related deaths. T2‐stage and poor tumor differentiation were associated with recurrences. Posttreatment QoL, facial function, and appearance were rated as good. Brachytherapy was the most expensive treatment modality.
Conclusion
Early‐stage lip SCC has a good prognosis, with a disease‐specific survival of 98.2% after a median follow‐up of 36 months, there was a high QoL and satisfaction at long‐term follow‐up. Based on the costs and the risk of locoregional recurrences, we believe that, for most noncomplex lip SCCs, MMS would be the most logical treatment option.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Dermatology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Oral and Maxillofacial Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Plastic & Reconstructive Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
ORCID profiles: Kira S van Hof
Cite
APA
van Hof, K. S., Wakkee, M., Sewnaik, A., Herkendaal, A. F., Tans, L., Mast, H., van den Bos, R. R., Mureau, M. A. M., Offerman, M. P. J., & Baatenburg de Jong, R. J. (2024). Long‐term outcomes, quality of life, and costs of treatment modalities for T1–T2 lip carcinomas. Oral Diseases. https://doi.org/10.1111/odi.14723
Vancouver
van Hof KS, Wakkee M, Sewnaik A, Herkendaal AF, Tans L, Mast H, et al. Long‐term outcomes, quality of life, and costs of treatment modalities for T1–T2 lip carcinomas. Oral Diseases. 2024. doi:10.1111/odi.14723
BibTeX
@article{vanHof2024,
author = {van Hof, Kira S and Wakkee, Marlies and Sewnaik, Aniel and Herkendaal, Aimée F and Tans, Lisa and Mast, Hetty and van den Bos, Renate R and Mureau, Marc A M and Offerman, Marinella P J and Baatenburg de Jong, Robert J},
title = {Long‐term outcomes, quality of life, and costs of treatment modalities for T1–T2 lip carcinomas},
journal = {Oral Diseases},
year = {2024},
doi = {10.1111/odi.14723}
}
EUVIMED